Abstract
Cardiomyopathies are categorized as extrinsic, being caused by external factors, such as hypertension, ischemia, inflammation, valvular dysfunction, or as intrinsic, which correspond to myocardial diseases without identifiable external causes. These so called primary cardiomyopathies can be categorized in four main forms: hypertrophic, dilated, restrictive, and arrhythmogenic right ventricular cardiomyopathy. Cardiomyopathies are diagnosed by clinical expression, echocardiography, electrocardiography, non-invasive imaging, and sometimes by cardiac catheterization to rule out external causes as ischemia. The two main forms of primary cardiomyopathies are the hypertrophic and dilated cardiomyopathies. Most of hypertrophic cardiomyopathy and 20-50% of dilated cardiomyopathy are familial showing a wide genetic and phenotypic heterogeneity. This review presents the current knowledge on the causative genes, molecular mechanisms and the genotype–phenotype relations of hypertrophic and dilated cardiomyopathies.
Keywords: Cardiomyopathy, hypertrophy, dilatation, genetics, mutation
Current Pharmaceutical Biotechnology
Title:Genetics of Hypertrophic and Dilated Cardiomyopathy
Volume: 13 Issue: 13
Author(s): Felix W. Friedrich and Lucie Carrier
Affiliation:
Keywords: Cardiomyopathy, hypertrophy, dilatation, genetics, mutation
Abstract: Cardiomyopathies are categorized as extrinsic, being caused by external factors, such as hypertension, ischemia, inflammation, valvular dysfunction, or as intrinsic, which correspond to myocardial diseases without identifiable external causes. These so called primary cardiomyopathies can be categorized in four main forms: hypertrophic, dilated, restrictive, and arrhythmogenic right ventricular cardiomyopathy. Cardiomyopathies are diagnosed by clinical expression, echocardiography, electrocardiography, non-invasive imaging, and sometimes by cardiac catheterization to rule out external causes as ischemia. The two main forms of primary cardiomyopathies are the hypertrophic and dilated cardiomyopathies. Most of hypertrophic cardiomyopathy and 20-50% of dilated cardiomyopathy are familial showing a wide genetic and phenotypic heterogeneity. This review presents the current knowledge on the causative genes, molecular mechanisms and the genotype–phenotype relations of hypertrophic and dilated cardiomyopathies.
Export Options
About this article
Cite this article as:
W. Friedrich Felix and Carrier Lucie, Genetics of Hypertrophic and Dilated Cardiomyopathy, Current Pharmaceutical Biotechnology 2012; 13 (13) . https://dx.doi.org/10.2174/1389201011208062467
DOI https://dx.doi.org/10.2174/1389201011208062467 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the AMP-Activated Protein Kinase for the Treatment of Type 2 Diabetes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Disruption of Circadian Rhythms and Sleep on Critical Illness and the Impact on Cardiovascular Events
Current Pharmaceutical Design Tandem Mass Spectrometry Newborn Screening for Inborn Errors of Intermediary Metabolism: Abnormal Profile Interpretation
Current Medicinal Chemistry Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Heart Failure in the Middle East
Current Cardiology Reviews Alternative Approach for Mitigation of Doxorubicin-Induced Cardiotoxicity using Herbal Agents
Current Clinical Pharmacology Meet Our Editorial Board Member
Current Vascular Pharmacology Mn-SOD and Chronic Inflammation of Gastric Mucosa
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cross-Talk Between Adipose Tissue Health, Myocardial Metabolism and Vascular Function: The Adipose-Myocardial and Adipose-Vascular Axes
Current Pharmaceutical Design Use of Peripheral Blood Stem Cells in Tissue Engineering
Current Tissue Engineering (Discontinued) Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules
Inflammation & Allergy - Drug Targets (Discontinued) Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research Regulation of Angiogenesis by the Small Heat Shock Protein αB-Crystallin
Current Angiogenesis (Discontinued) Polyamines and Related Nitrogen Compounds in the Chemotherapy of Neglected Diseases Caused by Kinetoplastids
Current Topics in Medicinal Chemistry Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells
Current Vascular Pharmacology Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Editorial[Hot Topic:Stem Cell Therapy for Cardiovascular Diseases:Are We Still at the Beginning of A Long Road?(Guest Editor:Lino M Goncalves)
Cardiovascular & Hematological Disorders-Drug Targets COVID-19 Effects on Geriatric Population and Failures of Aminoquinoline Therapy: Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccines in the Prevention and Treatment of COVID-19
Current Medicinal Chemistry Triple Threat: The Na+/Ca2+ Exchanger in the Pathophysiology of Cardiac Arrhythmia, Ischemia and Heart Failure
Current Drug Targets Genetic Lipodystrophies: Models for Insulin Resistance
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents